Skip to main content
Research project

Novel Pharmaceutical Agents (XF-drugs) to Prevent and Proactively Manage Bacterial Biofilm and Fungal Infections in Dynamic Model Systems

Project overview

National Biofilms Innovation Centre (NBIC), UK. Proof of Concept (POC) Round 1 (Research Grant). £147,727 (£65,994.50 from NBIC, £81,732.50 from Destiny Pharma).
Antibiotic-resistant bacteria, particularly within biofilms and fungi pose a significant healthcare threat including respiratory conditions, (e.g. Cystic Fibrosis) and chronic wounds such as diabetic foot ulcers (DFU). The purpose of this NBIC study is to examine the effectiveness of a novel antimicrobial-drug series in two mechanistically-distinct and clinically relevant model systems.


Lead researcher

Professor Jeremy Webb

Professor of Microbiology

Research interests

  • Microbial biofilms and their control
  • Adaptive biology and evolution of microorganisms
  • Biofilm-associated infection
Connect with Jeremy
Other researchers

Professor Charles Keevil

Professor In Environmental Health Care
Connect with Charles

Professor Saul Faust MBBS, FRCPCH, PhD, FHEA, OBE

Professor Paediatric Immunology & Infect
Connect with Saul

Collaborating research institutes, centres and groups

Research outputs